arrow
A

Aranzazu González del Alba

instituto de investigación sanitaria puerta de hierro-segovia de arana
H指数:22
被引数:2,358

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Therapeutic Alliances for Optimizing the Management of Patients with Prostate Cancer: SOGUG Multidisciplinary Expert Panel Recommendations

优化前列腺癌患者管理的治疗联盟:SOGUG多学科专家小组建议

2025-10-010
OAAI
Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish 'Cambados annual meeting' ( Feb , 10.1007/s12094-025-03850-z , 2025)

泌尿生殖系统肿瘤的临床进展与实践更新:西班牙多学科“坎巴多斯年会”2024年综述(2025年2月,10.1007/s12094-025-03850-z)

2025-04-040
PRE
Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish 'Cambados annual meeting'

泌尿生殖系统癌症的临床进展与实践更新:西班牙多学科“坎巴多斯年会”2024年综述

2025-02-170
PRE
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study

223镭治疗的转移性去势抵抗性前列腺癌患者的骨代谢生物标志物和生存率的前瞻性评估: PRORADIUM研究

2024-06-012
PRE
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
2023-12-153
PRE
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

转移性去势抵抗性前列腺癌患者疾病进展为醋酸阿比特龙加泼尼松后,醋酸阿比特龙加泼尼松联合多西他赛或多西他赛加泼尼松的II期随机试验: ABIDO-SOGUG试验

2022-11-017
OAAI
Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial

在一线醋酸阿比曲酮或恩扎鲁他胺治疗无症状骨转移的转移性去势抵抗性前列腺癌患者的镭223: 一项单臂II期试验

2022-09-017
PRE
Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)
2021-09-011
OAAI
PRORADIUM: Prospective analysis of the impact of germline mutations in homologous recombination (HR) genes on the response to radium-223 for metastatic castration resistant prostate cancer (mCRPC)
2021-09-013
OAAI
Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era
2021-06-014
PREAI
Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM)

性别对医学肿瘤学家的工作满意度和领导力的影响: 西班牙医学肿瘤学会 (SEOM) 的调查

2021-04-017
OAAI
223Ra in asymptomatic patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide

223Ra在无症状的转移性去势抵抗性前列腺癌 (mCRPC) 患者 (pts) 中进展为一线醋酸阿比特龙或恩扎鲁他胺

2020-09-011
OAAI
Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)

醋酸阿比特龙联合泼尼松与卡巴他赛作为多西他赛一线治疗转移性去势耐药前列腺癌的后续治疗的疗效和安全性: 前瞻性观察研究 (CAPRO) 的结果

2019-08-051
OAAI
The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer
2019-03-2320
OAAI